TC BioPharm Debt

TCBP Stock  USD 0.56  0.02  3.70%   
At this time, TC BioPharm's Net Debt To EBITDA is relatively stable compared to the past year. As of 12/03/2024, Debt To Equity is likely to grow to 0.57, while Short Term Debt is likely to drop slightly above 290.1 K. . TC BioPharm's financial risk is the risk to TC BioPharm stockholders that is caused by an increase in debt.
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.16747529
Current Value
0.16
Quarterly Volatility
0.2989334
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, TC BioPharm's Total Current Liabilities is relatively stable compared to the past year. As of 12/03/2024, Liabilities And Stockholders Equity is likely to grow to about 10 M, while Non Current Liabilities Total is likely to drop slightly above 1.4 M.
  
Check out the analysis of TC BioPharm Fundamentals Over Time.

TC BioPharm Bond Ratings

TC BioPharm Holdings financial ratings play a critical role in determining how much TC BioPharm have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for TC BioPharm's borrowing costs.
Piotroski F Score
1
Very WeakView
Beneish M Score
(6.36)
Unlikely ManipulatorView

TC BioPharm Holdings Debt to Cash Allocation

TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity.

TC BioPharm Total Assets Over Time

TC BioPharm Assets Financed by Debt

The debt-to-assets ratio shows the degree to which TC BioPharm uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

TC BioPharm Debt Ratio

    
  16.0   
It seems most of the TC BioPharm's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the TC BioPharm's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of TC BioPharm, which in turn will lower the firm's financial flexibility.

TC BioPharm Corporate Bonds Issued

TCBP Short Long Term Debt Total

Short Long Term Debt Total

1.71 Million

At this time, TC BioPharm's Short and Long Term Debt Total is relatively stable compared to the past year.

Understaning TC BioPharm Use of Financial Leverage

TC BioPharm's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to TC BioPharm's current equity. If creditors own a majority of TC BioPharm's assets, the company is considered highly leveraged. Understanding the composition and structure of TC BioPharm's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Short and Long Term Debt Total1.8 M1.7 M
Net Debt-661.5 K-628.4 K
Short Term Debt305.3 K290.1 K
Short and Long Term Debt588.1 K558.7 K
Net Debt To EBITDA 0.05  0.05 
Debt To Equity 0.56  0.57 
Interest Debt Per Share 48.42  46.00 
Debt To Assets 0.17  0.16 
Long Term Debt To Capitalization 0.32  0.29 
Total Debt To Capitalization 0.36  0.38 
Debt Equity Ratio 0.56  0.57 
Debt Ratio 0.17  0.16 
Cash Flow To Debt Ratio(7.05)(7.40)
Please read more on our technical analysis page.

Pair Trading with TC BioPharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with TCBP Stock

  0.64A Agilent TechnologiesPairCorr
  0.87ME 23Andme HoldingPairCorr
  0.72VALN Valneva SE ADRPairCorr

Moving against TCBP Stock

  0.86DRUG Bright Minds Biosciences TrendingPairCorr
  0.81SABSW SAB BiotherapeuticsPairCorr
  0.73VCYT VeracytePairCorr
  0.71VERA Vera TherapeuticsPairCorr
  0.7VANI Vivani MedicalPairCorr
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for TCBP Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.